Teratogenic drugs and their drug interactions with hormonal contraceptives.

Abstract

The US Food and Drug Administration (FDA) Guidance for Industry-Drug Interaction Studies, recommends that a potential human teratogen needs to be studied in vivo for effects on contraceptive steroids.(1) This article highlights the need to evaluate the drug-drug interactions (DDIs) between drugs with teratogenic potential and hormonal contraceptives (HCs… (More)
DOI: 10.1002/cpt.384

Topics

  • Presentations referencing similar topics